Journal of Fluorescence

, Volume 21, Issue 2, pp 739–745 | Cite as

Spectrofluorimetric Assessment of Metoclopramide Hydrochloride Using Terbium Doped in PMMA Matrix Optical Sensor

Original Paper


A new, simple and accurate spectrofluorimetric method for the determination of metoclopramide hydrochloride was developed. The metoclopramide hydrochloride can remarkably enhance the luminescence intensity of the Tb3+ ion doped in PMMA matrix at λex = 360 nm in methanol at pH 6.9. The intensity of the emission band at 545 nm of Tb3+ ion doped in PMMA matrix is increased due to the energy transfer from metoclopramide hydrochloride to Tb3+ in the excited stated. The effect of different parameters, e.g., pH, temperature, Tb3+ concentration, foreign ions that control the fluorescence intensity of the produced ion associate was critically investigated. The calibration curve of the emission intensity at 545 nm shows linear response of metoclopramide over a concentration range of 5 × 10−5–5.0 × 10−8 M with detection limit of 8.7 × 10−10 M. The method was used successfully for the determination of metoclopramide in pharmaceutical preparations and human serum. The average recovery of 99.48% with standard deviation of 0.32% and 96.98% with standard deviation of 0.4%, of pharmaceutical preparations and human serum respectively, were obtained which compared will with the results obtained from standard LC method of average recovery 99.04% and standard deviation of 0.6% and average recovery of 98.19% with standard deviation of 0.6% of pharmaceutical preparations and human serum, respectively.


Metoclopramide hydrochloride Terbium Optical sensor Energy transfer Luminescence Intensity PMMA 


  1. 1.
    Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H (2006) Eur J Pharm Biopharm 64:246–254PubMedCrossRefGoogle Scholar
  2. 2.
    Buna M, Aaron JJ, Prognon P, Mahuzier G (1996) Analyst 121:1551–1556PubMedCrossRefGoogle Scholar
  3. 3.
    Revanasiddappa HD, Manju B (2001) J Pharm Biomed Anal 25:631–638PubMedCrossRefGoogle Scholar
  4. 4.
    Raghuveer S, Rao BE, Sricasteva CMR, Vatsa DK (1992) East Pharm 35:125–144Google Scholar
  5. 5.
    British Pharmacopoeia (1998) Her Majesty’s Stationery Office, LondonGoogle Scholar
  6. 6.
    Chmielewska A, Konieczna L, Plenis A, Lamparczyk H (2006) J Chromatogr B 839:102–111CrossRefGoogle Scholar
  7. 7.
    Royo-Herrero M, Mellado-Romero A, Martinez-Calatayud J (1998) Talanta 47:223–228PubMedCrossRefGoogle Scholar
  8. 8.
    Moussa BA (2000) J Pharm Biomed Anal 23:1045–1055PubMedCrossRefGoogle Scholar
  9. 9.
    Fan J, Wang AJ, Feng SL, Wang JJ (2005) Talanta 66:236–243PubMedCrossRefGoogle Scholar
  10. 10.
    Editorial Committee of the Pharmacopoeia of People’s Republic of China, The Pharmacopoeia of People’s Republic of China (2000) Chemical Industry Press, Beijing, p. 144Google Scholar
  11. 11.
    Radwan MA (1998) Anal Lett 31:2397–2405Google Scholar
  12. 12.
    Venkateshwaran TG, Kimng DT, Stewart JT (1995) J Liq Chromatogr Relat Technol 18:117–126CrossRefGoogle Scholar
  13. 13.
    Foda NH (1994) Anal Lett 27:549–559Google Scholar
  14. 14.
    El-Sayed YM, Khidr SH, Niazy EM (1994) Anal Lett 27:55–70Google Scholar
  15. 15.
    The United States Pharmacopoeia (2000) XXIV Revision, The Nation Formulary XIX Rockville, USP ConventionGoogle Scholar
  16. 16.
    Chang YS, Ku YR, Wen KC, Ho LK (2000) J Liq Chromatogr Relat Technol 23:2009–2019CrossRefGoogle Scholar
  17. 17.
    Kerr R, Jung L (1990) Spectra 2000 Deux-Mille. 18:33–34Google Scholar
  18. 18.
    Poban CV, Frutos P, Lastres JL, Frutos G (1996) J Pharm Biomed Anal 15:131–138CrossRefGoogle Scholar
  19. 19.
    Riggs KW, Szeitz A, Rurak DW, Multib AE, Abbott FS, Axelson JL (1994) J Chromatogr B Biomed Appl 660:315–325PubMedCrossRefGoogle Scholar
  20. 20.
    Mostafa GAE (2003) J Pharm Biomed Anal 31:515–521PubMedCrossRefGoogle Scholar
  21. 21.
    Wang ZH, Zhang HZ, Zhou SP, Dong WJ (2001) Talanta 53:1133–1138PubMedCrossRefGoogle Scholar
  22. 22.
    Norouzi P, Ganjali MR, Matloobi P (2005) Electrochem Commun 7:333–338CrossRefGoogle Scholar
  23. 23.
    Farghaly OA, Taher MA, Naggar AH, El-Sayed AY (2005) J Pharmaceut Biomed Anal 38:14–20Google Scholar
  24. 24.
    Hanna GM, Lau-Cam CA (1991) Drug Dev Ind Pharm 17:975–980CrossRefGoogle Scholar
  25. 25.
    Al-Arfaj NA (2004) Talanta 62:255–263PubMedCrossRefGoogle Scholar
  26. 26.
    Hun X, Zhang Z (2008) J Pharm Biomed Anal 47:670–676PubMedCrossRefGoogle Scholar
  27. 27.
    Attia MS, Khalil MMH, Ayman A, Abdel-Shafi GM, Salvatore F, Giuseppe C, Finocchiaro P, Abdel-Mottaleb MSA (2007) Int J Photoenergy, ID 12530. doi: 10.1155/2007/12530
  28. 28.
    Files LA, Hirschy LM, Winefordner JD (1985) J Pharm Biomed Anal 3:95–100PubMedCrossRefGoogle Scholar
  29. 29.
    Suleiman MS, Najib NM, El-Sayed YM, Badwan A (1989) Analyst 114:365–368PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Chemistry, Faculty of ScienceAin Shams UniversityCairoEgypt
  2. 2.Environmental Biotechnology, Genetic Engineering and Biotechnology InstituteMenoufia UniversitySadatEgypt
  3. 3.Pharmaceutical and Medicinal Chemistry DepartmentNational Research CentreCairoEgypt

Personalised recommendations